Homepage
Author:
Outlook Therapeutics, Inc.
Posted Date:
April 7, 2026
Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA
Outlook Therapeutics, Inc.
April 7, 2026
Outlook Therapeutics Announces Closing of $5.0 Million Public Offering
Outlook Therapeutics, Inc.
March 25, 2026
Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering
Outlook Therapeutics, Inc.
March 24, 2026
Outlook Therapeutics Announces Proposed Public Offering
Outlook Therapeutics, Inc.
March 23, 2026
Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note
Outlook Therapeutics, Inc.
March 16, 2026
Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg)
Outlook Therapeutics, Inc.
March 5, 2026
Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland
Outlook Therapeutics, Inc.
February 19, 2026
Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
Outlook Therapeutics, Inc.
February 17, 2026
Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter
Outlook Therapeutics, Inc.
February 12, 2026
